A novel combination of an investigational intravesical drug delivery system designed to provide sustained release of gemcitabine into the bladder (Gem-iDRS, Inlexzo) and systemic treatment with the ...

When a doctor suspects bladder cancer, they will order a series of tests which may include urine tests (urinalysis or urine cytology), a cystoscopy to visualize the inside of the bladder, and/or a CT ...

The extent of the bladder cancer — how far it has spread — matters. Your care team needs to know if your cancer sits on or in the first lining of your bladder (non-muscle invasive), if it goes into ...

As a potential biomarker of treatment response, ctDNA and utDNA analyses were performed before systemic therapy, at restaging, and for responders at the beginning of adjuvant nivolumab. ctDNA was ...

Approximately 40% of patients with muscle-invasive bladder cancer achieve a clinical complete response after neoadjuvant ...

SWOG S1602: A phase III randomized trial to evaluate BCG strain differences and priming with intradermal BCG before intravesical therapy for BCG-naïve high-grade non-muscle invasive bladder cancer ...

Erda-iDRS delivers erdafitinib into the bladder over three months, enabling localised therapy and reducing systemic exposure.

Most people don’t think about their bladder very often. But as you get older, it’s something that requires a little bit more attention. Here’s what you need to know about how your bladder changes as ...